The role of nitric oxide in oral diseases

Archives of Oral Biology

Volumn 48, Issue 2, 2003, Pages 93-100

  Brennan, P A ^a,d   Thomas, G J ^b   Langdon, J D ^c  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d NONE   (United Kingdom)

Author keywords

Cancer; Nitric oxide; Oral disease; Review

Indexed keywords

EID: 0037316673     PISSN: 00039969     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-9969(02)00183-8     Document Type: Review

References (58)

1. Moncada S, Martin JF. Evolution of nitric oxide. Lancet 1993;341:1511.
2. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelial-derived relaxing factor. Nature 1987;327:524-526.
3. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhari G. Endothelial-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9269.
4. Wink DA, Vodovotz Y, Laval D, Laval F, Dewhirst DW, Mitchell JB. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998;19:711-721.
5. Wink DA, Osawa Y, Darbyshire JF, Jones CR, Eshenaur SC, Nims RW. Inhibition of cytochromes P450 by nitric oxide and a nitric oxide-releasing agent. Arch Biochem Biophys 1993;300:115-123.
6. Radomski MW, Martin JF, Moncada S. Synthesis of nitric oxide by the haemocytes of the American horseshoe crab. Philos Trans R Soc Lond Biol Sci 1991;334:129-133.
7. Ignarro IJ, Lippton H, Edwards JC. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981;218:739-749.
8. Synder SH, Bredt DS. Biological roles of nitric oxide. Sci Am 1992;266:28-35.
9. Hope BT, Michael GJ, Knigge KM, Vincent SR. Neuronal NADPH diaphorase is a nitric oxide synthase. Proc Natl Acad Sci USA 1991;88:2811-2814.
10. Anbar M, Gratt BM. The possible role of nitric oxide in the physiopathology of pain associated with temporomandibular joint disorders. J Oral Maxillofac Surg 1998;56:872-882.
11. Pipili-Synetos E, Sakkoula E, Haralapoulos G, Andriopoulou P, Peristeris P, Maragoudakis ME. Evidence that nitric oxide is an endogenous antiangiogenic mediator. Br J Pharmacol 1994;11:894-902.
12. Lau YT, Ma WC. Nitric oxide inhibits migration of cultured endothelial cells. Biochem Biophys Res Commun 1996;221: 670-674.
13. Shan SQ, Rosner GL, Braun RD, Hahn J, Pearce C, Dewhirst MW. Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma. Br J Cancer 1997;76:429-437.
14. Gallo O, Masini E, Morbidelli L. Role of nitric oxide in angiogenesis and tumour progression in head and neck cancer. J Natl Cancer Inst 1998;90:587-596.
15. Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997;99:2625-2634.
16. Parenti A, Morbidelli L, Cui XL, Douglas JG, Hood JD, Granger HJ, et al. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J Biol Chem 1998;273:4220-4226.
17. Hibbs JBJ, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988;157:87-94.
18. Thomsen LL, Miles DW. Role of nitric oxide in tumour progression: Lessons from human tumours. Cancer Metastasis Rev 1998;17:107-118.
19. Marletta MA. Nitric oxide synthase structure and mechanism. J Biol Chem 1993;269:12231-12234.
20. Sessa WC. The nitric oxide synthase family of proteins. J Vasc Res 1994;31:131-143.
21. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci 1994;91: 5212-5216.
22. Abu-Soud HM, Stuehr DJ. Nitric oxide synthases reveal a role for calmodulin in controlling electron transfer. Proc Natl Acad Sci 1993;90:10769-10772.
23. Vodovotz Y, Kwon NS, Pospischil M, Manning J, Paik J, Nathan C. Inactivation of nitric oxide synthase after prolonged incubation with IFN-γ and bacterial lipopolysaccharide. J Immunol 1994;152:4110-4118.
24. Melillo G, Musso T, Sica A, Taylor LS, Cox GW, Varesio L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 1995;182:1683-1693.
25. Forrester K, Ambs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci 1996;93:2442-2447.
26. Förstermann U, Kleinert H. Nitric oxide synthase: expression and expressional control of the three isoforms. Naunyn Schmiedeberg Arch Pharmacol 1995;352:351-364.
27. Shimizu Y, Sakai M, Umemura Y, Ueda H. Immunohistochemical localisation of nitric oxide synthase in normal human skin: expression of endothelial-type and inducible-type nitric oxide synthase in keratinocytes. J Dermatol 1997;24:80-87.
28. Brennan PA, Umar T, Zaki GA, Langdon JD, Spedding AV, Buckley J, et al. Are myoepithelial cells responsible for the widespread expression of inducible nitric oxide synthase in pleomorphic adenoma? An immunohistochemical study. J Oral Pathol Med 2000;29:279-283.
29. Paquette DW, Williams RC. Modulation of host inflammatory mediators as a treatment strategy for periodontal diseases. Periodontol 2000;24:239-252.
30. Lohinai Z, Stachlewitz R, Virag L, Szekely AD, Hasko G, Szabo C. Evidence for reactive nitrogen species formation in the gingivomucosal tissue. J Dent Res 2001;80:470-475.
31. Daghigh F, Borghaei RC, Thornton RD, Bee JH. Human gingival fibroblasts produce nitric oxide in response to proinflammatory cytokines. J Periodontol 2002;73:392-400.
32. Takeichi O, Hayashi M, Tsurumachi T, Tomita T, Ogihara H, Ogiso B, et al. Inducible nitric oxide synthase activity by interferon-γ-producing cells in human radicular cysts. Int Endod J 1999;32:124-130.
33. Shimauchi H, Takayama S, Narikawa-Kiji M, Shimabukuro Y, Okada H. Production of interleukin-8 and nitric oxide in human periapical lesions. J Endod 2001;27:749-752.
34. Brennan PA, Umar T, Palacios-Callender M, Spedding AV, Mellor T, Buckley J, et al. A study to assess inducible nitric oxide synthase expression in oral lichen planus. J Oral Pathol Med 2000b;29:249-254.
35. Ohashi M, Iwase M, Nagumo M. Elevated production of salivary nitric oxide in oral mucosal diseases. J Oral Pathol Med 1999;28:355-359.
36. Bentz BG, Haines GK, Lingen MW, Pelzer HJ, Hanson DG, Radosevich JA. Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol 1999; 108:781-787.
37. Mollaoglu M. Oral lichen planus: a review. Br J Oral Maxillofac Surg 2000;38:370-377.
38. Liu RH, Hotchkiss JH. Potential genotoxicity of chronically elevated nitric oxide: a review. Mutation Res 1995;339:73-89.
39. Lala PK, Orucevic A. Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metastasis Rev 1998;17:91-106.
40. Murata J, Tada M, Iggo RD, Sawamura Y, Shinohe Y, Abe H. Nitric oxide as a carcinogen: analysis by functional yeast assay of inactivating p53 mutations induced by nitric oxide. Mutation Res 1997;379:211-218.
41. Slomiany BL, Slomiany A. Nonsteroidal anti-inflammatory drugs impair oral mucosal repair by eliciting disturbances in endothelin-converting enzyme-1 and constitutive nitric oxide synthase. J Physiol Pharmacol 2001;52:81-92.
42. Slomiany BL, Piotrowski J, Piotrowski E, Slomiany A. Activation of apoptotic caspase-3 and NOS2 in buccal mucosa with chronic alcohol ingestion. J Biochem Mol Biol Int 1998;45:1199-1209.
43. Bentz BG, Haines K, Hanson DG, Radosevich JA. Endothelial constitutive nitric oxide synthase (ecNOS) localisation in normal and neoplastic salivary tissue. Head Neck 1998;20: 304-309.
44. Konttinen YT, Platts LA, Tuominen S, Eklund KK, Santavirta N, Tornwall J, et al. Role of nitric oxide in Sjogren's syndrome. Arthritis Rheum 1997;40:875-883.
45. Felley-Bosco E, Mirkovitch J, Ambs S, Mace K, Pfeifer A, Keefer LK, et al. Nitric oxide and ethinylnitrosourea: relative mutagenicity in the p53 tumor suppressor and hypoxanthine-phosphoribosyltransferase genes. Carcinogenesis 1995;16:2069-2074.
46. Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM, Khan MA, et al. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer 1998;78:233-239.
47. Chen YK, Lin LM. Immunohistochemical expression of inducible nitric oxide synthase in DMBA-induced hamster buccal pouch carcinogenesis. Oral Oncol 2000;36:221-224.
48. Rosbe KW, Prazma J, Petrusz P, Mims W, Ball SS, Weissler MC. Immunohistochemical characterization of nitric oxide synthase activity in squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg 1995;113:541-549.
49. Murrell GAC, Jang D, Williams RJ. Nitric oxide activates matrix metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 1995;206:15-21.
50. Shang ZJ, Li JR, Li ZB. Effects of exogenous nitric oxide on oral squamous cell carcinoma: An in vitro study. J Oral Maxillofac Surg 2002;60:905-910.
51. Chen YK, Hsue SS, Lin LM. The mRNA expression of inducible nitric oxide synthase in DMBA-induced hamster buccal-pouch carcinomas using reverse transcription-polymerase chain reaction. J Oral Pathol Med 2002;31:82-86.
52. Gavilanes J, Moro MA, Lizasoain J, Lorenzo P, Pérez A, Leza JC, et al. Nitric oxide synthase activity in human squamous cell carcinoma of the head and neck. Laryngoscope 1999;109:148-152.
53. Brennan PA, Conroy B, Spedding AV. Expression of NOS2 and p53 in oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol 2000c;90:624-629.
54. Thomsen LL, Scott JMJ, Topley P, Knowles RG, Keerie AJ, Frend AJ. Selective inhibition of inducible nitric oxide synthase inhibits tumour growth in vivo. Studies with 1400W, a novel inhibitor. Cancer Res 1997;57:3300-3304.
55. Brennan PA, Palacios-Callender M, Spedding AV, Zaki GA, Langdon JD. Type II nitric oxide synthase expression correlates with lymph node status in oral squamous cell carcinoma. J Oral Pathol Med 2001;30:129-134.
56. Brennan PA, Palacios-Callender M, Spedding AV, Zaki GA, Langdon JD. Does type II nitric oxide synthase expression correlate with cellular proliferation in oral squamous cell carcinoma and dysplasia? Head Neck 2001;27:217-222.
57. Brennan PA, Palacios-Callender M, Umar T, Tant S, Langdon JD. Expression of type 2 nitric oxide synthase and p21 in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2002; 31:200-205.
58. Brennan PA, Umar T, Wilson AW, Mellor TK. Expression of type 2 nitric oxide synthase and vascular endothelial growth factor in oral dysplasia. J Oral Maxillofac Surg 2002;60: 1455-1460.